In the last trading session, 1.5 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) were traded, and its beta was 1.72. Most recently the company’s share price was $1.19, and it changed around -$0.05 or -4.03% from the last close, which brings the market valuation of the company to $173.20M. HRTX currently trades at a discount to its 52-week high of $3.93, offering almost -230.25% off that amount. The share price’s 52-week low was $0.72, which indicates that the current value has risen by an impressive 39.5% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 2.55 million shares, with the 3-month average coming to 1.85 million.

Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Heron Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.

Heron Therapeutics Inc (NASDAQ:HRTX) trade information

Instantly HRTX has showed a red trend with a performance of -4.03% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8950 on recent trading dayincreased the stock’s daily price by 37.2%. The company’s shares are currently down -30.00% year-to-date, but still down -32.00% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is -34.62% down in the 30-day period. We can see from the shorts that 28.81 million shares have been sold at a short interest cover period of 20.19 day(s).

The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 83.0% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $9.

Heron Therapeutics Inc (HRTX) estimates and forecasts

Heron Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -62.81 percent over the past six months and at a 83.75% annual growth rate that is well above the industry average of 15.60%. The year-over-year growth rate is expected to be 18.76%, up from the previous year.

Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 37.37M in revenue for the current quarter. 3 analysts expect Heron Therapeutics Inc to make 140.87M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 34.23M and 127.04M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 9.15%. Forecasts for the next quarter put sales growth at 10.88%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%. Heron Therapeutics Inc earnings are expected to increase by 83.75% in 2024, but the outlook is positive 47.50% per year for the next five years.

HRTX Dividends

Heron Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-12.

Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.71% of Heron Therapeutics Inc shares, and 81.60% of them are in the hands of institutional investors. The stock currently has a share float of 82.18%. Heron Therapeutics Inc stock is held by 219.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 17.6678% of the shares, which is about 26.71 million shares worth $93.5 million.

VANGUARD GROUP INC, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.